In this webinar, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX.
 
Dr Klein shares how Dewpoint applies insights into the subcellular organisation of biochemical processes into membrane-less compartments to discover novel drug targets and revolutionary drugs for diseases with high unmet need, including amyotrophic lateral sclerosis (ALS) and Rett Syndrome.

Dr Clark’s presentation will cover the intersection of medicinal chemistry and drug discovery as well as how this can help address the unmet medical need for new therapeutics in the neuropsych space.

Professor Roberts will explore how an integrated in vitro seizure liability assay can benefit drug discovery for companies exploring central nervous system diseases. 

What you will learn:

• Where are the breakthroughs in neuroscience research?
• How are advanced technologies proving beneficial to drug discovery and development?
• How is the current unmet need within drug discovery and development for central nervous system (CNS) disorders providing opportunity?
  
  A Q&A session follows the webinar presentations.
  
  Watch the webinar on-demand now!